Literature DB >> 23007860

Transcriptome and small RNA deep sequencing reveals deregulation of miRNA biogenesis in human glioma.

Lynette M Moore1, Virpi Kivinen, Yuexin Liu, Matti Annala, David Cogdell, Xiuping Liu, Chang-Gong Liu, Raymond Sawaya, Olli Yli-Harja, Ilya Shmulevich, Gregory N Fuller, Wei Zhang, Matti Nykter.   

Abstract

Altered expression of oncogenic and tumour-suppressing microRNAs (miRNAs) is widely associated with tumourigenesis. However, the regulatory mechanisms underlying these alterations are poorly understood. We sought to shed light on the deregulation of miRNA biogenesis promoting the aberrant miRNA expression profiles identified in these tumours. Using sequencing technology to perform both whole-transcriptome and small RNA sequencing of glioma patient samples, we examined precursor and mature miRNAs to directly evaluate the miRNA maturation process, and examined expression profiles for genes involved in the major steps of miRNA biogenesis. We found that ratios of mature to precursor forms of a large number of miRNAs increased with the progression from normal brain to low-grade and then to high-grade gliomas. The expression levels of genes involved in each of the three major steps of miRNA biogenesis (nuclear processing, nucleo-cytoplasmic transport, and cytoplasmic processing) were systematically altered in glioma tissues. Survival analysis of an independent data set demonstrated that the alteration of genes involved in miRNA maturation correlates with survival in glioma patients. Direct quantification of miRNA maturation with deep sequencing demonstrated that deregulation of the miRNA biogenesis pathway is a hallmark for glioma genesis and progression.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23007860      PMCID: PMC3857031          DOI: 10.1002/path.4109

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  48 in total

1.  Reduced expression of Dicer associated with poor prognosis in lung cancer patients.

Authors:  Yoko Karube; Hisaaki Tanaka; Hirotaka Osada; Shuta Tomida; Yoshio Tatematsu; Kiyoshi Yanagisawa; Yasushi Yatabe; Junichi Takamizawa; Shinichiro Miyoshi; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Sci       Date:  2005-02       Impact factor: 6.716

2.  Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha.

Authors:  Brandi N Davis; Aaron C Hilyard; Peter H Nguyen; Giorgio Lagna; Akiko Hata
Journal:  Mol Cell       Date:  2010-08-13       Impact factor: 17.970

3.  A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs.

Authors:  Tae-Min Kim; Wei Huang; Richard Park; Peter J Park; Mark D Johnson
Journal:  Cancer Res       Date:  2011-03-08       Impact factor: 12.701

4.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

5.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.

Authors:  Alejandra Bruna; Rachel S Darken; Federico Rojo; Alberto Ocaña; Silvia Peñuelas; Alexandra Arias; Raquel Paris; Avelina Tortosa; Jaume Mora; Jose Baselga; Joan Seoane
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

6.  A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells.

Authors:  Sonia A Melo; Catia Moutinho; Santiago Ropero; George A Calin; Simona Rossi; Riccardo Spizzo; Agustin F Fernandez; Veronica Davalos; Alberto Villanueva; Guillermo Montoya; Hiroyuki Yamamoto; Simo Schwartz; Manel Esteller
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

7.  Extensive modulation of a set of microRNAs in primary glioblastoma.

Authors:  S A Ciafrè; S Galardi; A Mangiola; M Ferracin; C-G Liu; G Sabatino; M Negrini; G Maira; C M Croce; M G Farace
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

8.  The nuclear RNase III Drosha initiates microRNA processing.

Authors:  Yoontae Lee; Chiyoung Ahn; Jinju Han; Hyounjeong Choi; Jaekwang Kim; Jeongbin Yim; Junho Lee; Patrick Provost; Olof Rådmark; Sunyoung Kim; V Narry Kim
Journal:  Nature       Date:  2003-09-25       Impact factor: 49.962

9.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

10.  SMAD proteins control DROSHA-mediated microRNA maturation.

Authors:  Brandi N Davis; Aaron C Hilyard; Giorgio Lagna; Akiko Hata
Journal:  Nature       Date:  2008-06-11       Impact factor: 49.962

View more
  12 in total

1.  Suppression and epigenetic regulation of MiR-9 contributes to ethanol teratology: evidence from zebrafish and murine fetal neural stem cell models.

Authors:  Dana L Pappalardo-Carter; Sridevi Balaraman; Pratheesh Sathyan; Eric S Carter; Wei-Jung A Chen; Rajesh C Miranda
Journal:  Alcohol Clin Exp Res       Date:  2013-06-25       Impact factor: 3.455

2.  Extraction of Molecular Features through Exome to Transcriptome Alignment.

Authors:  Prakriti Mudvari; Kamran Kowsari; Charles Cole; Raja Mazumder; Anelia Horvath
Journal:  J Metabolomics Syst Biol       Date:  2013-08-22

3.  The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.

Authors:  Brittany C Parker; Matti J Annala; David E Cogdell; Kirsi J Granberg; Yan Sun; Ping Ji; Xia Li; Joy Gumin; Hong Zheng; Limei Hu; Olli Yli-Harja; Hannu Haapasalo; Tapio Visakorpi; Xiuping Liu; Chang-Gong Liu; Raymond Sawaya; Gregory N Fuller; Kexin Chen; Frederick F Lang; Matti Nykter; Wei Zhang
Journal:  J Clin Invest       Date:  2013-01-09       Impact factor: 14.808

4.  Reductions in the expression of miR-124-3p, miR-128-1, and miR-221-3p in pediatric astrocytomas are related to high-grade supratentorial, and recurrent tumors in Mexican children.

Authors:  Pilar Eguía-Aguilar; Mario Pérezpeña-Díazconti; Eduardo Benadón-Darszon; Fernando Chico-Ponce de León; Luis Gordillo-Domínguez; Samuel Torres-García; Stanislaw Sadowinski-Pine; Francisco Arenas-Huertero
Journal:  Childs Nerv Syst       Date:  2014-04-10       Impact factor: 1.475

5.  MIR-491: CDKN2A tumor suppressor co-pilot.

Authors:  Lynette M Moore; Wei Zhang
Journal:  Oncoscience       Date:  2015-08-21

6.  Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing.

Authors:  Rahul Agrawal; Priyatama Pandey; Prerana Jha; Vivek Dwivedi; Chitra Sarkar; Ritu Kulshreshtha
Journal:  BMC Genomics       Date:  2014-08-17       Impact factor: 3.969

Review 7.  Targeting microRNAs: a new action mechanism of natural compounds.

Authors:  Qian Lin; Leina Ma; Zhantao Liu; Zhihong Yang; Jin Wang; Jia Liu; Guohui Jiang
Journal:  Oncotarget       Date:  2017-02-28

8.  Links between the oncoprotein YB-1 and small non-coding RNAs in breast cancer.

Authors:  Cherie Blenkiron; Daniel G Hurley; Sandra Fitzgerald; Cristin G Print; Annette Lasham
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

Review 9.  MicroRNAs as biomarkers for CNS disease.

Authors:  Pooja Rao; Eva Benito; André Fischer
Journal:  Front Mol Neurosci       Date:  2013-11-26       Impact factor: 5.639

10.  Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma.

Authors:  Xia Li; Yuexin Liu; Kirsi J Granberg; Qinhao Wang; Lynette M Moore; Ping Ji; Joy Gumin; Erik P Sulman; George A Calin; Hannu Haapasalo; Matti Nykter; Ilya Shmulevich; Gregory N Fuller; Frederick F Lang; Wei Zhang
Journal:  Oncogene       Date:  2014-04-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.